Gonadorelin

Gonadorelin (GnRH) is a powerful decapeptide and a gonadotropin-releasing hormone agonist. Its primary action is to stimulate the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). It has established medical applications for infertility, menstrual cycle irregularities, and hypogonadism, and for diagnostic testing of the pituitary. Major research milestones indicate its therapeutic value in breast and prostate cancer treatment and in the management of Alzheimer's disease.

Gonadorelin Structure

• Formula: C55H75N17O13
• Molecular Weight: 1182.29 g/mol
• Sequence: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Gonadorelin Effects

Gonadorelin Research and Breast Cancer Prevention

The risk of breast cancer is significantly associated with lifetime exposure to estrogen. Gonadorelin is investigated as a preventative agent by suppressing ovarian estrogen production, offering a cost-effective, primary prevention strategy against estrogen-receptor-positive breast cancer in high-risk postmenopausal women. The potential for risk reduction is substantial, estimated at 60% over 10 years and 70% over 15 years [1]. Crucially, by acting at the source, gonadorelin could enhance the long-term effectiveness of anti-estrogen drugs by circumventing resistance [4].

Investigations in postmenopausal women with hyperandrogenism demonstrated effective hormonal reduction without serious adverse effects, suggesting an alternative treatment path to traditional estrogen replacement therapy.

Gonadorelin a Breakthrough in Prostate Cancer

Prostate cancer is highly susceptible to hormonal control. The early use of GnRH led to the successful development of medical castration and, subsequently, the highly efficacious Combined Androgen Blockade therapy (CAB). CAB, which relies on GnRH analogues and other treatments, is one of oncology's greatest successes. Combined with early detection, the CAB protocol is responsible for curing 99% of all prostate cancer.

Gonadorelin May Reduce Dementia Risk

The reproductive hormone LH is recognized for influencing cognitive function via the hippocampus [9]. Research links high LH levels to amyloid-beta (Abeta) plaques [10], which are implicated in Alzheimer's disease. The therapeutic goal is to reduce LH levels to alleviate Abeta pathology [11] while simultaneously maintaining protective testosterone levels. The GnRH analogue leuprolide has shown a decreased risk of developing Alzheimer's [12], which is linked to its ability to down-regulate LH by suppressing CAR effects [13]. Current research is also focused on gonadorelin analogues' influence on the interaction between APOE and MS4A4A genetic factors in Abeta plaque formation [14].

Gonadorelin Research

Gonadorelin is a research peptide built upon decades of Gonadotropin-releasing hormone (GnRH) research. Milestones include developing a near-curative protocol for prostate cancer and establishing promising avenues for breast cancer prevention and neurodegenerative disease treatment. Gonadorelin demonstrates minimal adverse effects in mice, with excellent subcutaneous bioavailability. Gonadorelin for human application remains restricted to educational and scientific exploration. Human consumption remains prohibited. Only licensed researchers may obtain Gonadorelin if they are accredited investigators.

Article Author

The referenced literature was researched, compiled, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine.

Scientific Journal Author

Dr. Giorgio Secreto is a leading scientist at the IRCCS National Cancer Institute in Italy. His specialization is the role of androgens in breast cancer. His foundational work on GnRH's effect on ovarian androgen reduction is acknowledged in references [1] and [3]. He does not endorse or promote this compound, and no affiliation exists between Peptide Sciences and this researcher.

Referenced Citations

G. Secreto et al., "A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women," Breast Cancer Res. Treat., vol. 158, no. 3, pp. 553–561, 2016. D. V. Spicer and M. C. Pike, "Sex steroids and breast cancer prevention," J. Natl. Cancer Inst. Monogr., no. 16, pp. 139–147, 1994. G. Secreto, P. Muti, M. Sant, E. Meneghini, and V. Krogh, "Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy," Endocr. Relat. Cancer, vol. 24, no. 11, pp. C21–C29, 2017. E. S. Volleard, A. P. van Beck, F. A. J. Verburg, A. Rozs, and J. A. Land, "Gonadotropin releasing hormone agonist treatment in premenopausal women with hyperandrogenism of ovarian origin," J. Clin. Endocrinol. Metab., vol. 96, no. 5, pp. 1197–1201, May 2011. F. Labrie, "Hormonal therapy of prostate cancer," Prog. Brain Res., vol. 182, pp. 321–341, 2010. F. Labrie, "GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer," Endocr. Relat. Cancer, vol. 21, no. 4, pp. R301–317, Aug. 2014. F. Labrie, "Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology," J. Steroid Biochem. Mol. Biol., vol. 145, pp. 144–156, Jan. 2015. F. Labrie, "Keynote of endocrinology in the victory against prostate cancer," Bull. Cancer (Paris), vol. 93, no. 9, pp. 849–868, Sep. 2006. V. Burnham, C. Sundby, A. Laman-Maharg, and J. Thornton, "Luteinizing hormone acts at the hippocampus to dampen spatial memory," Horm. Behav., vol. 89, pp. 55–63, 2017. C. V. Rao, "Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women," Reprod. Sci. Thousand Oaks Calif, vol. 24, no. 3, pp. 355–368, 2017. J. Lin et al., "Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease," J. Neuropathol. Exp. Neurol., vol. 69, no. 3, pp. 253–261, Mar. 2010. R. L. Bowen, T. Butler, and C. S. Atwood, "Nad All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease," J. Clin. Oncol., vol. 34, no. 23, p. 2800, Aug. 2016. M. A. Smith, P. L. Bowen, R. O. Nguyen, G. Perry, C. S. Atwood, and A. A. Rimm, "Putative Gonadorelin Releasing Hormone Against Therapy and Dementia: An Application of Medicare Hospitalization Claims Data to PLA JAD, vol. 63, no. 4, pp. 1259–1277, 2018. A. Clelems, J. E. Vargas, and J. R. Gonzalez, "APOE and MS4A4A interact with GnRH signaling in Alzheimer's disease: Disrupting in mab and Alzheimer Dement. J. Alzheimers Assoc., vol. 13, no. 4, pp. 493–497, Apr. 2017.